You are here

  • Home
  • Archive
  • Volume 79, Issue 5
  • Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study

Article metrics

Article menu

This article has corrections. Please see:

Download PDFPDF

Spondyloarthritis
Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study

 

Online download statistics by month:

Online download statistics by month: April 2020 to March 2024

AbstractFullPdf
Apr 202014321423569
May 2020691682294
Jun 2020251240130
Jul 202012111984
Aug 202012912779
Sep 2020143133121
Oct 202020219895
Nov 202021020699
Dec 202013513167
Jan 202115014285
Feb 202120019776
Mar 202115315162
Apr 202112912261
May 202119518578
Jun 202111911347
Jul 202115214774
Aug 2021207203103
Sep 2021184172111
Oct 2021216194127
Nov 202115514783
Dec 202113713249
Jan 202212311550
Feb 202214114159
Mar 202215614762
Apr 202215615498
May 202215014963
Jun 202214413648
Jul 202212011741
Aug 202213211938
Sep 202214413847
Oct 202218018178
Nov 202216615647
Dec 202211411044
Jan 202314613461
Feb 20231059934
Mar 202310710145
Apr 2023524441
May 2023999030
Jun 2023757026
Jul 2023646040
Aug 2023564430
Sep 202311310919
Oct 202323122427
Nov 202332931624
Dec 202314411534
Jan 202411911333
Feb 2024878340
Mar 20249186124
Total885585153777